Therapeutic area intelligence for Stem Cell Therapy with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Regeneron →

Assets

Acelity →

Shenzhen →

Recent signals(2)

ClinicalJuly 27, 2026

Shenzhen Geno-Immune initiates trial on cfMSCs for immune-related disorders

A clinical trial is evaluating the safety and efficacy of clonal fetal mesenchymal stem cells for immune-related disorders.

ClinicalJune 17, 2026

Phase I/II Trial of Adipose-derived Stem Cells for Burn Scarring Initiated in Denmark

A phase I/II trial (ScarASC) is underway to evaluate the efficacy of allogeneic adipose-derived stem cells for treating hypertrophic scars in burn survivors.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.